QGEN
QIAGEN NV
NYSE · Healthcare · Medical - Diagnostics & Research · NL
$50.33
−1.04%Price chart
Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29Nov 3Nov 6
Key dataNov 6, 2026
Open$50.42
From 52W high−9.58%
Volume3.39M
Market cap$10.39B
P/E (TTM)25.8x
P/S (TTM)4.9x
Div yield5.48%
Key dataNov 6, 2026
Open
$50.42
From 52W high
−9.58%
Volume
3.39M
Market cap
$10.39B
ValuationView details →
P/E (Fwd)
19.8x
EV/EBITDA
16.0x
P/E (TTM)
25.8x
RSI (14)
68.9
MomentumView details →
1D Return
−1.04%
YTD Return
+6.47%
SummaryUpdated Jun 1, 2026
QIAGEN N.V. (NASDAQ:QGEN) is a Netherlands-based multinational biotechnology company founded in 1986 that specializes in molecular diagnostics and life sciences research technologies. Originally established as a spin-off from the University of Düsseldorf, QIAGEN went public in 1996 and has grown through both organic expansion and strategic acquisitions to become a leading provider of sample preparation and molecular testing solutions. The company serves customers across molecular diagnostics, academic research, pharmaceutical development, and applied testing markets worldwide, with operations spanning over 35 countries and headquarters in Venlo, the Netherlands.
Similar companies
Latest newsMore news →
QIAGEN shareholders approved Jonathan M. Pratt’s appointment as a Managing Director and member of the company’s Managing Board.1d agoQIAGEN N.V. reported quarterly earnings of $0.65 per share, compared with $0.64 per share a year earlier.3d agoQIAGEN reported preliminary third-quarter 2026 net sales of $548 million and adjusted diluted EPS of $0.65, both unchanged at constant exchange rates.17d ago